These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39092454)

  • 1. Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations.
    Goedecke T; Martirosyan L; Gault N; Seifert K; Morales DR; Bahri P; Strassmann V; Huber M; Straus S
    Pharmacoepidemiol Drug Saf; 2024 Aug; 33(8):e5874. PubMed ID: 39092454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
    Holm JEJ; Ruppert JG; Ramsden SD
    Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety Studies.
    Grupstra RJ; Goedecke T; Gardarsdottir H
    Clin Pharmacol Ther; 2024 Nov; 116(5):1252-1258. PubMed ID: 38994581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the Safety of Medicines in the European Union: From Signals to Action.
    Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
    Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
    Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
    Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.
    Essink SCM; Zomerdijk IM; Straus SMJM; Gardarsdottir H; De Bruin ML
    Drug Saf; 2023 Oct; 46(10):1007-1020. PubMed ID: 37658281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
    Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
    Drug Saf; 2021 Feb; 44(2):193-209. PubMed ID: 33125664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.